Viewing Study NCT00228878



Ignite Creation Date: 2024-05-05 @ 12:03 PM
Last Modification Date: 2024-10-26 @ 9:19 AM
Study NCT ID: NCT00228878
Status: TERMINATED
Last Update Posted: 2016-08-10
First Post: 2005-09-27

Brief Title: Effect Pulsatile IV Insulin Therapy on the Quality of Life in Patients With Types 1 and 2 Diabetes
Sponsor: Florida Atlantic University
Organization: Florida Atlantic University

Study Overview

Official Title: Quality of Life With and Without Pulsatile IV Insulin Therapy in Diabetes
Status: TERMINATED
Status Verified Date: 2016-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Administrative
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to determine if restoring normal metabolic function in patients with either type I or type II diabetes can improve the impact of the consequences of diabetic complications on the overall quality of life of diabetic patients Patients are treated once a week with pulsatile intravenous insulin therapy mimicking normal insulin secretion A 44 item questionnaire is completed prior to the start of the treatment and quarterly thereafter with detailed analysis performed to measure progress and outcomes
Detailed Description: It is known that the glucose metabolic pathway glycolysis is the primary fuel generator in the brain and nerve tissue the heart and vascular tissue the eye the kidney and the liver Deficient metabolic states such as seen in the glucose metabolism of diabetics can lead to sequelae These damaging effects are exacerbated by altered cellular metabolites specifically the increase in catabolic and decrease in anabolic factors It has been shown over the past twenty years that normalization of metabolism in diabetic patients can be accomplished by mimicking the normal endogenous insulin pattern ie in pulses Pulsatile insulin infusion has been demonstrated to reverse the diabetic metabolic state from primary fat utilization to carbohydrate utilization This has been correlated with a stabilization of kidney function in patients with overt diabetic nephropathy stabilization of blood glucoses stabilization of blood pressure patterns and reversal of hypoglycemic unawareness

The Diabetes Impact Measurement Scale was originally developed to assess quality of life in patients with types 1 and 2 Diabetes Mellitus This study measures whether the reversal of abnormal metabolism in patients with diabetes is correlated with an improvement in their quality of lifeThe respiratory quotient RQ is a measurement of CO2 exhaled and O2 inhaled and is proportionate to the fuel sources being used by the body primarily the liver over short periods of time The higher the RQ the more glucose and less alternative fuel sources are being utilized Following the RQ change helps determine the effectiveness of physiological insulin administration in increasing anabolic functions in diabetic individuals By improving the bodys glucose metabolism and thereby causing beneficial effects of anabolic factors the possibility of serious complications can be decreased In addition the use of oral carbohydrate at the same time along with the physiologic insulin administration stimulates the appropriate gut hormones which augment this effect a response which cannot be duplicated with intravenous glucose The purpose of our studies is to determine whether the physiologic administration of insulin along with the augmenting effect of oral carbohydrates will normalize metabolism in diabetic patients and improve their quality of life indices

The RQ is determined by the use of a metabolic cart Individuals breathe into a mask for 3-5 minutes after a rest period of 30 or more minutes The ratio of exhaled volume of CO2 to the inhaled volume of O2 is determined as the RQ The physiologic range is 07 to13 Individuals using fat as a primary fuel have a ratio of 07 protein or mixed fuels is 08-09 and carbohydrate is 09-10 Those taking excessive calories will have RQs higher than 105 The RQ can be followed serially and this is done before and after each pulsatile IV insulin treatment during the 3 successive sessions on a single treatment day The amount of intravenous insulin and oral glucose given is determined by the RQ changes during the previous sessionpulsatile IV insulin therapy encourages the glucose metabolism in diabetics to normalize in multiple organs especially muscle retina liver kidney and nerve endings The process fundamentally requires the administration of high dose insulin pulses similar to those found in non diabetic humans by their pancreas into the surrounding portal circulation Oral carbohydrates are given simultaneously to augment the process and prevent hypoglycemia The process is monitored by frequent glucose levels and respiratory quotients RQ RQ is measured by a metabolic cart which determines the ratio VCO2 VO2 This ratio is specific for the fuel used at any one time by the body The glucose levels are monitored to keep glucose levels appropriate and the RQ determines the need to readjust the infusion protocol in each patient for subsequent insulin infusion sessionsPatient is evaluated post session and discharged when stable

Frequent monitoring of RQ is necessary as these levels change rapidly depending on the fuel being utilized by the body Pulsatile IV insulin therapy shifts metabolism from primarily fatty acid metabolism to primarily glucose metabolism This shift is reflected by the increase in respiratory quotient However during rest periods the RQ may fall back to lower levels Therefore RQs are done at the beginning and at the end of each insulin infusion session of 1 hour in order to appropriately monitor and adjust insulin and carbohydrate loads to reach optimal activation in each session

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None